Saturday 17 October 2026 Export NEOG’s income statement to Excel — free account

Neogen Corporation

Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025. In the quarter to August 2026, revenue grew 6.51%, EPS fell 132.1%, free cash flow grew 135.8% and total debt fell 2.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

11.81 0.46 −3.75%

Follow NEOG

Alert me

Market cap: $2.7B
P/E: 0.0×
Fwd P/E: −36.3×
Dividend yield: —
F-score: 5/9
Altman Z: 1.11
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	2	1	—	—	—	—	—	1	—	1
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.89%

Capital & Financial Ratios $m

Market Cap 2,680.00

Revenue 884.01

Net Income (56.14)

Free Cash Flow 49.85

Net Debt 602.20

Current Ratio 3.90

Debt/Equity 0.37

P/E ratio 0.00

Fwd P/E (36.30)

P/S ratio 2.91

P/B ratio 1.23

Past 5Y EPS Growth —

This Y EPS Growth 1.04%

Next Y EPS Growth 24.74%

Next Y revenue growth 1.68%

Next 5Y EPS Growth 17.57%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 17.32%

10-year low 10-year high

P/B against its own 10 years 29.23%

10-year low 10-year high

EV/Sales against its own 10 years 17.84%

10-year low 10-year high

EV/FCF against its own 10 years 46.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	171	129	186	172
Receivables	173	153	147	136
Inventory	189	191	144	146
Other	—	50	68	70
	589	577	605	583

	2024	2025	2026	Q'26
Payables	83	80	79	78
ST’ Debt	2	19	—	—
Other	23	39	31	34
	154	174	158	150

Compound Annual Growth %

	10y	5y	3y
Sales	10.48%	13.19%	1.91%
Cash Flow	8.94%	0.52%	26.57%
Earnings	0.00%	0.00%	0.00%
Book Value	17.87%	20.02%	(12.59%)

Revenue $m

	Aug	Nov	Feb	May	Year
’26	223	—	—	—	—
’26	209	225	211	225	870
’25	217	231	221	225	895
’24	229	230	229	237	924
’23	132	230	218	242	822
’22	128	131	128	140	527
’21	109	115	117	127	468

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	13	—	—	—	—
’26	11	19	23	30	83
’25	(18)	40	19	16	58
’24	23	16	(30)	27	35
’23	(14)	(19)	(17)	91	41
’22	23	18	7	20	68
’21	25	22	12	22	81

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	5	—	—	—	—
’26	(13)	8	11	26	32
’25	(52)	23	(13)	1	(41)
’24	(8)	(9)	(62)	3	(76)
’23	(27)	(30)	(32)	66	(24)
’22	22	14	0	8	44
’21	21	16	3	15	54

Fiscal quarters ending in the months shown.

EPS $

	Aug	Nov	Feb	May	Year
’26	(0.05)	—	—	—	—
’26	0.17	(0.07)	(0.08)	(0.05)	(0.04)
’25	(0.06)	(2.10)	(0.05)	(2.82)	(5.03)
’24	0.01	(0.02)	(0.01)	(0.02)	(0.04)
’23	0.05	(0.19)	0.04	0.03	(0.12)
’22	0.16	0.10	0.05	0.14	0.45
’21	0.15	0.15	0.13	0.15	0.57

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	22.32	26.05	25.30	24.46	38.62	10.49	14.44	11.46	3.87	6.89	Analyst estimates 2027–2029 Powerpack
	High	32.22	48.69	39.92	41.35	48.85	45.60	24.10	20.72	13.41	14.26
People
People	Employees	1,413	1,546	1,682	1,764	1,841	2,108	2,640	997	975	817
	Revenue/emp, $m	0.25	0.26	0.25	0.24	0.25	0.25	0.31	0.93	0.92	1.07
Income, $m
Income, $m	Revenue	358	398	414	418	468	527	822	924	895	870
	Gross margin, %	47.15	46.81	46.34	46.94	45.91	46.10	49.36	50.19	47.10	46.93
	EBT	67	73	73	72	75	60	(22)	(14)	(1,133)	(9)
	EBT margin, %	18.61	18.46	17.62	17.29	16.07	11.42	(2.68)	(1.55)	(126.65)	(1.03)
	Net income	44	63	60	59	61	48	(23)	(9)	(1,092)	(8)
	Depreciation	15	17	18	18	21	24	93	125	1,198	124
Per share, $
Per share, $	Revenue	3.54	3.87	3.99	3.98	4.40	4.90	4.35	4.27	4.12	4.00
	Earnings	0.43	0.61	0.58	0.57	0.57	0.45	(0.12)	(0.04)	(5.03)	(0.04)
	Cash flow	0.60	0.67	0.62	0.82	0.76	0.63	0.22	0.16	0.27	0.38
	Capex	(0.14)	(0.20)	(0.14)	(0.23)	(0.25)	(0.23)	(0.34)	(0.51)	(0.46)	(0.24)
	Free cash flow	0.45	0.47	0.47	0.59	0.51	0.41	(0.13)	(0.35)	(0.19)	0.15
	Book value	4.67	5.45	6.15	6.90	7.89	8.24	16.59	14.52	9.55	9.62
	Shares, m	101	103	104	105	106	108	189	217	217	218
Valuation, ×
Valuation, ×	P/E	55.52	62.44	49.01	63.58	79.34	58.80	0.00	0.00	0.00	0.00
	P/S	6.70	9.77	7.06	9.03	10.37	5.41	4.02	3.08	1.38	2.23
	P/B	5.09	6.94	4.58	5.21	5.78	3.21	1.05	0.91	0.60	0.93
	EV/Sales	6.30	9.24	6.41	8.21	9.56	4.68	4.80	3.86	2.23	2.95
	EV/FCF	49.37	76.33	54.02	55.52	82.36	56.62	(165.10)	(46.93)	(48.41)	80.24
Cash, $m
Cash, $m	Operating cash flow	60	69	64	86	81	68	41	35	58	83
	Capex	(15)	(21)	(15)	(24)	(27)	(24)	(65)	(111)	(99)	(51)
	Free cash flow	46	48	49	62	54	44	(24)	(76)	(41)	32
Balance, $m
Balance, $m	Working capital	257	337	411	489	538	549	440	435	403	446
	Total debt	—	—	—	1	1	1	888	891	894	794
	Net debt	(144)	(211)	(268)	(343)	(380)	(380)	643	720	765	608
	Shareholders’ equity	472	560	638	725	840	887	3,134	3,144	2,071	2,093
Returns, %
Returns, %	ROA	8.95	11.02	9.16	7.97	7.09	5.05	(0.82)	(0.21)	(27.33)	(0.23)
	ROIC	12.37	12.56	11.49	11.03	10.07	7.22	0.62	0.95	(23.38)	(0.50)
	ROE	10.00	12.24	10.05	8.73	7.78	5.59	(1.14)	(0.30)	(41.88)	(0.38)

Negative figures in brackets.

All 10 years →

Fiscal years to May 2026 · latest quarter Aug 2026 · fundamentals updated 13 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IRTC iRhythm Holdings, Inc.	$3.6B	— (loss-making)	— (loss-making)	+20.08% (above 0%: growing)	n/m	+116.98% (above 0%: growing)	72.80%	(1.13%)	Compare
NEOG Neogen Corporation	$2.7B	— (loss-making)	— (loss-making)	+6.51% (above 0%: growing)	n/m	+135.75% (above 0%: growing)	47.35%	(0.81%)
TMDX TransMedics Group, Inc.	$2.7B	16.0×	34.1×	+20.70% (above 0%: growing)	−59.22% (below 0%: shrinking)	−87.62% (below 0%: shrinking)	59.59%	12.50%	Compare
UFPT UFP Technologies, Inc.	$2.3B	31.2×	23.6×	+15.07% (above 0%: growing)	+20.63% (above 0%: growing)	−35.77% (below 0%: shrinking)	29.27%	16.15%	Compare
BFLY Butterfly Network, Inc.	$2.1B	— (loss-making)	— (loss-making)	+39.47% (above 0%: growing)	n/m	−113.85% (below 0%: shrinking)	71.41%	(41.90%)	Compare
AXGN AxoGen, Inc.	$2.1B	— (loss-making)	— (loss-making)	+23.06% (above 0%: growing)	n/m	−17.36% (below 0%: shrinking)	72.67%	(3.09%)	Compare
INSP Inspire Medical Systems, Inc.	$2.0B	14.8×	93.5×	−7.60% (below 0%: shrinking)	n/m	+322.84% (above 0%: growing)	85.48%	(0.26%)	Compare
ESTA Establishment Labs Holdings Inc.	$1.8B	— (loss-making)	— (loss-making)	+31.66% (above 0%: growing)	n/m	+2.75% (above 0%: growing)	70.64%	(6.35%)	Compare
ATEC Alphatec Holdings, Inc.	$1.7B	— (loss-making)	— (loss-making)	+15.07% (above 0%: growing)	n/m	−146.87% (below 0%: shrinking)	72.17%	(0.89%)	Compare
Median of peers	$2.1B	16.0×	34.1×	+20.39%	—	−26.56%	71.79%	(1.01%)

All 149 Medical Devices stocks →

Neogen Corporation (NEOG) key facts

Concern: Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
Neogen Corporation (NEOG) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NEOG traded at $11.81, a market capitalization of $2.7 billion.
Return on equity was −0.38% and debt-to-equity 0.37.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.11 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 13, 2026.